egfr

Documents about egfr

• Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)#1497904ClinicalTrials.gov
• Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC#880363ClinicalTrials.gov
• TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis#903829ClinicalTrials.gov
• Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)#1442614ClinicalTrials.gov
• Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model#345346OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC#893566ClinicalTrials.gov
• ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC#969230ClinicalTrials.gov
• Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients#1419719ClinicalTrials.gov
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations#904116ClinicalTrials.gov
• Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors#1212393ClinicalTrials.gov
• EGFR isoforms and gene regulation in human endometrial cancer cells#176310Zenodo (CERN)
• EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations#1094687ClinicalTrials.gov
• Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review#304159Europe PMC
• A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer#1484201ClinicalTrials.gov
• EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC#832710ClinicalTrials.gov
• TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors#895122ClinicalTrials.gov
• CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)#1112067ClinicalTrials.gov
• Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC#1350435ClinicalTrials.gov
• Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients#1306750ClinicalTrials.gov
• Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)#1310377ClinicalTrials.gov
• Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients#827072ClinicalTrials.gov
• Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer#1095475ClinicalTrials.gov
• EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment#1243149ClinicalTrials.gov
• Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure#1260739ClinicalTrials.gov
• Asia Pacific and Russia Diagnostic Study for EGFR Testing#1454635ClinicalTrials.gov
• First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation#1093100ClinicalTrials.gov
• Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC#914842ClinicalTrials.gov
• Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC#1029804ClinicalTrials.gov
• Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)#905846ClinicalTrials.gov
• MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC#1185084ClinicalTrials.gov
• EGFR-targeted Therapy for Gastric Cancer#1125922ClinicalTrials.gov
• Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy#1337856ClinicalTrials.gov
• Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia#1260462ClinicalTrials.gov
• Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients#146458ClinicalTrials.gov
• Platforms for investigating evolutionary changes in EGFR – Gurken signaling#348768RUcore, Rutgers University Community Repository
• GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification#896281ClinicalTrials.gov
• A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure#904319ClinicalTrials.gov
• Osimertinib for Advanced EGFR-positive NSCLC Patients#1431300ClinicalTrials.gov
• Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial#846904ClinicalTrials.gov
• Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure#1075742ClinicalTrials.gov
• Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors#1198612ClinicalTrials.gov
• Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation#825938ClinicalTrials.gov
• Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC#1162913ClinicalTrials.gov
• A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer#1243424ClinicalTrials.gov
• Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)#474773ClinicalTrials.gov
• Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants#1384623ClinicalTrials.gov
• Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC#160372ClinicalTrials.gov
• In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule#857404ClinicalTrials.gov
• PDX Models From EGFR Mutant Tumors#1087108ClinicalTrials.gov
• IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC#1101851ClinicalTrials.gov